Article

Extramacular Drusen Commonly Observed in Eyes with AMD

Author(s):

An analysis of data from AREDS2 suggests extramacular drusen in eyes with AMD are more frequent with an increased drusen burden within the macula.

Emily Y. Chew, MD

Credit: National Eye Institute

Emily Y. Chew, MD

Credit: National Eye Institute

Key Highlights

  • Extramacular drusen are commonly observed in eyes with age-related macular degeneration (AMD).
  • Data from AREDS2 suggest extramacular drusen are more frequent with an increased drusen burden observed within the macula.
  • Extramacular drusen may not have additional risk in the progression from intermediate AMD to late AMD.
  • Investigators observed extramacular drusen represented a small area (< 0.5 mm2) in approximately half of eyes.
  • Eyes with extramacular drusen exhibited larger macular drusen size and area compared to eyes without extramacular drusen (P <.001).
  • Extramacular drusen were not associated with progression to late AMD.

Extramacular drusen were commonly observed in eyes with age-related macular degeneration (AMD), according to a retrospective analysis of the Age-Related Eye Disease Study 2 (AREDS2).1

The analysis suggests extramcular drusen in eyes with AMD are more frequent with an increased drusen burden within the macula, but may not indicate additional risk in the progression from intermediate AMD to late AMD.

“In eyes with intermediate AMD, extramacular drusen do not confer additional risk to previously identified risk factors in progression to late AMD,” wrote the investigative team.

The investigative team, led by Emily Y. Chew, MD, set out to identify the prevalence of extramacular drusen and their role in the progression of AMD, using 4168 eyes (2998 participants) with AMD in one of both eyes enrolled in AREDS2. AREDS2 was a 5-year multicenter study of nutritional supplements.

The team evaluated baseline 3-field 30-degree color photpgrahs for drusen characteristics outside the macular grid, including size, area, and location. Then, the characteristics of extramacular drusen were compared with those of drusen within the macula. Main outcomes for the study were progression rates to late AMD.

In their results, investigators observed extramacular drusen represented a small area (< 0.5 mm2) in approximately half of eyes. Although extramacular drusen were observed in 3624 (86.9%) eyes, data showed they represented that small area in 50.3% of eyes and only 17.5% of eyes exhibited an area of >1 disc area.

Investigators additionally found eyes with extramacular drusen exhibited larger macular drusen size and area compared to eyes without extramacular drusen (P <.001). They noted extramacular drusen were not associated with progression to late AMD.

In further analysis, the hazard ratio adjusted for baselien age, sex, smoking, AMD severity level, and reticular pseudodrusen for the 4043 eyes at risk of developing late AMD over 5 years was 1.17 (95% confidence interval [CI], 0.88 – 1.54; P = .27) for geographic atrophy. In addition, the hazard ratio for neovascular AMD was 0.96 (95% CI, 0.76 - 1.2; P = .7).

References

  1. Domalpally A, Xing B, Pak JW, et al. Extramacular Drusen and progression of age-related macular degeneration. Ophthalmology Retina. 2023;7(2). doi:10.1016/j.oret.2022.08.001
Related Videos
Marcelo Kugelmas, MD | Credit: South Denver Gastroenterology
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
© 2024 MJH Life Sciences

All rights reserved.